Early generations of PIM inhibitors, including SGI-1176, a non-ATP-mimetic pan-PIM kinase inhibitor, reached phase I clinical trials for the treatment of non-Hodgkin lymphoma and refractory prostate cancer. Here, PIM1 is linked to Familial prostate cancer.